CLDI (Calidi Biotherapeutics) Moat Score: 3/10 (As of Jun. 24, 2026)


CLDI Calidi Biotherapeutics Inc CLDI
12 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is Calidi Biotherapeutics Moat Score?

Calidi Biotherapeutics CLDI +0.64% 12 Moat Score is 3 as of Jun. 24, 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,405 Biotechnology companies, Calidi Biotherapeutics ranks better than 75.52% on this metric.

Calidi Biotherapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Calidi Biotherapeutics has No Moat: Calidi Biotherapeutics Inc is in the early stages of development with limited market presence and brand strength. It lacks significant intellectual property or regulatory barriers, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Calidi Biotherapeutics might have No Moat - Very weak/transient advantages.

Calidi Biotherapeutics  (AMEX:CLDI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Calidi Biotherapeutics Moat Score Related Terms

CLDI vs CMND, BIXT, GRI: Moat Score Comparison

For the Biotechnology subindustry, Calidi Biotherapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calidi Biotherapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's Moat Score falls into.


CLDI
12GF Score
Calidi Biotherapeutics Inc CLDI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Calidi Biotherapeutics (CLDI) has a Moat Score of 3 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Calidi Biotherapeutics ranks #344 out of 1405 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Calidi Biotherapeutics' Moat Score too high?
Calidi Biotherapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Calidi Biotherapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Calidi Biotherapeutics ranks #344 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Moat Score compare to CMND and BIXT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #344 out of 1405 companies for Moat Score. This places Calidi Biotherapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Calidi Biotherapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Calidi Biotherapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Moat Score is 3 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score

Get the complete analysis for CLDI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price